Allogene Therapeutics (ALLO) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 90.6% versus a loss of 4.8%. Over five years, PBYI leads with a +64.8% price change compared with -91.5% for ALLO. Puma Biotechnology is the larger company by market cap ($514.7 million vs $483.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | PBYI |
|---|---|---|
| Share price | $1.40 | $9.97 |
| Market cap | $483.69M | $514.65M |
| 1-day change | -2.10% | +1.63% |
| YTD return | +2.19% | +67.56% |
| 1-year return | -4.76% | +90.63% |
| 5-year return | -91.50% | +64.79% |
| P/E ratio (TTM) | — | 19.55 |
| Forward P/E | — | 28.49 |
| EPS (TTM) | $-0.66 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $10.10 |
| 52-week low | $1.04 | $4.58 |
| Distance from 52-week high | -68.61% | -1.29% |
| Analyst consensus | none | none |
| Avg. price target upside | +542.86% | — |
| Average volume | 5.65M | 320.69K |
| Shares outstanding | 345.49M | 51.62M |
| Employees | 150 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed ALLO by 95.4 percentage points over the past year.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
ALLO vs PBYI FAQ
Which is bigger, Allogene Therapeutics or Puma Biotechnology?
Puma Biotechnology (PBYI) is larger, with a market capitalization of $514.65M compared with $483.69M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or PBYI?
PBYI returned +90.63% over the past 12 months, compared with -4.76% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Puma Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Allogene Therapeutics and Biotechnology: Pharmaceutical Preparations for Puma Biotechnology.